EUVIMEDEUVIMED entdecken
Crossref

Time Toxicity in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine Plus Cisplatin With or Without Durvalumab

Naohiro Okano, Angelo Pirozzi, Conor O'Donnell, Masato Hayashi, Pedro Luiz Serrano Uson Junior, Celine Hoyek, Oluseyi Abidoye, Cody Eslinger, Binbin Zheng-Lin, Natalie M. Elliott, Elizabeth A. Raupach, Yumei Zhou und 16 weitere

JCO Oncology Advances · 2026-01 · 3 (1)

DOI: 10.1200/oa-25-00126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-01. Verfasst von Naohiro Okano und 27 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE For patients with advanced biliary tract cancer (BTC), cancer-related time spent in health care systems, time toxicity, represents a critical but understudied burden affecting quality of life. This study aimed to quantify time toxicity in patients receiving first-line systemic therapy and evaluate whether the addition of durvalumab to gemcitabine plus cisplatin (GC) increases health care contact time. METHODS This international, multicenter, retrospective cohort study included patients with advanced BTC seen between January 2019 and April 2024 at Mayo Clinic Enterprise (US), and between January 2021 and April 2024 at Kyorin University Hospital (Japan), and Hospital Israelita Albert Einstein (Brazil). Patients received GC plus durvalumab (GCD) or GC. Time toxicity was recorded from treatment initiation until discontinuation or last follow-up during first-line systemic therapy. Multiple regression analysis identified factors associated with high time toxicity. RESULTS Among 193 patients (102 GCD, 91 GC; median age 65 years; 50% male; 49% Eastern Cooperative Oncology Group performance status [PS] 0), median time on treatment (TOT) was 156 days (95% CI, 122 to 190). The median proportion of total time toxicity was 14.4% (IQR, 10.9-20.6). Planned visits accounted for 11.9%, while unplanned visits were infrequent (1.8%). Time toxicity strongly correlated with TOT ( r = 0.824) and progression-free survival ( r = 0.827). Despite longer treatment in the GCD group than the GC group (212 v 134 days; P = .027), total time toxicity was similar (27 v 18 days; P = .19). Younger age and poor PS were independent factors of higher time toxicity. CONCLUSION Time toxicity represents a meaningful metric that allows for more comprehensive integration of the net benefit in patients with advanced BTC with a limited lifespan.

Zitieren

APA

Okano, N., Pirozzi, A., O'Donnell, C., Hayashi, M., Junior, P. L. S. U., Hoyek, C., Abidoye, O., Eslinger, C., Zheng-Lin, B., Elliott, N. M., Raupach, E. A., Zhou, Y., Petit, J., Ahn, D., Sonbol, M. B., Wu, C., Nishioka, M., Sato, T., Teixeira, M. F., …, & Borad, M. J. (2026). Time Toxicity in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine Plus Cisplatin With or Without Durvalumab. JCO Oncology Advances, 3(1). https://doi.org/10.1200/oa-25-00126

Vancouver

Okano N, Pirozzi A, O'Donnell C, Hayashi M, Junior PLSU, Hoyek C, et al. Time Toxicity in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine Plus Cisplatin With or Without Durvalumab. JCO Oncology Advances. 2026;3(1). doi:10.1200/oa-25-00126

BibTeX
@article{Okano2026,
  author = {Okano, Naohiro and Pirozzi, Angelo and O'Donnell, Conor and Hayashi, Masato and Junior, Pedro Luiz Serrano Uson and Hoyek, Celine and Abidoye, Oluseyi and Eslinger, Cody and Zheng-Lin, Binbin and Elliott, Natalie M. and Raupach, Elizabeth A. and Zhou, Yumei and Petit, Joachim and Ahn, Daniel and Sonbol, Mohamad Bassam and Wu, Christina and Nishioka, Mariko and Sato, Taro and Teixeira, Maria Fernanda and Sforzin, Isabella and Babiker, Hani M. and Majeed, Umair and Tran, Nguyen H. and Rimassa, Lorenza and Nagashima, Fumio and Hironaka, Shuichi and Bekaii-Saab, Tanios and Borad, Mitesh J.},
  title = {Time Toxicity in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine Plus Cisplatin With or Without Durvalumab},
  journal = {JCO Oncology Advances},
  year = {2026},
  volume = {3},
  number = {1},
  doi = {10.1200/oa-25-00126}
}
Kostenlos starten →